viewCannPal Animal Therapeutics Ltd

CannPal Animal Therapeutics files new patent application as industry-leading research is recognised

The company’s research results into cannabinoid treatments for animals have been presented at a leading veterinary conference.

Lead drug candidate CPAT-01 is being developed for pain and inflammation control in dogs

CannPal Animal Therapeutics Ltd (ASX:CP1) continues to demonstrate its leading position in developing unique cannabinoid-based treatment for companion animals by filing a further provisional patent application.

This application, which incorporates results of CannPal’s ongoing research, relates to CPAT-01, the company’s lead drug candidate in development for pain and inflammation control in dogs.

Strengthening company’s IP

The invention relates to a composition comprising a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD).

It builds on an earlier filed provisional patent application for the CPAT-01 formulation and seeks to further strengthen CannPal’s Intellectual Property (IP).

READ: CannPal Animal Therapeutics R&D research to be published in leading veterinary journal

The filing comes hot on the heels of recognition of the company’s extensive research at the 2019 AVA Innovation, Research and Development Symposium in Perth yesterday.

Run by the Australian Veterinary Association, it is Australia’s largest veterinary conference and attracted around 1,400 veterinarians.

CannPal’s head of R&D Dr Margaret Curtis presented on the company’s phase I research results for CPAT-01.

Study results presented

She presented on the pharmacokinetic, safety, gene expression and inflammatory biomarker results from CannPal’s robust randomised three group parallel pharmacokinetic study completed in 2018 for CPAT-01.

Dr Curtis said: “The Innovation Symposium was a fantastic opportunity to showcase the breadth and depth of CannPal’s research to the veterinary fraternity in Australia.

“It was a pleasure to share some of the exciting data that CannPal is generating with the wider scientific community, which we believe can help contribute to the advancement of cannabinoid-derived therapeutic research across all species.”

The research abstract will also reach more than 5,000 through publication in Australia’s premier veterinary scientific journal, the Australian Veterinary Journal.

READ: CannPal Animal Therapeutics sees lucrative opportunity in cannabinoids-based animal health market

CannPal’s founder and managing director Layton Mills said that the presentation and AVJ publication were significant milestones.

“There is significant demand from pet owners for cannabinoid-derived therapeutics, but veterinarians don’t yet have a thought leader providing them with reliable data or regulatory approved products.

“The AVJ publication is the first step in CannPal establishing ourselves as the provider of that data, and hopefully of regulatory approved, safe and effective veterinary medicines.

“This is an important step in building a trusting relationship with vets as we get closer towards commercialising our products through various regulatory pathways.”

Quick facts: CannPal Animal Therapeutics Ltd

Price: 0.13 AUD

Market: ASX
Market Cap: $12.11 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CannPal Animal Therapeutics Ltd named herein, including the promotion by the Company of CannPal Animal Therapeutics Ltd in any Content on the...



CannPal Animal Therapeutics leveraged to 'lucrative potential' of growing market

CannPal Animal Therapeutics Ltd (ASX:CP1) founder and managing director Layton Mills speaks to Proactive Investors about the innovative pet pharmaceutical company, which operates in the medical cannabis space. "The goal for the company is really to develop products that can address clear,...

on 25/6/18

3 min read